dimyristoylphosphatidylcholine has been researched along with Colorectal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ichihara, H; Matsumoto, Y; Matsuoka, Y; Nakagawa, S; Ueoka, R; Yoshida, K | 1 |
| Hino, M; Ichihara, H; Matsumoto, Y; Ueoka, R; Umebayashi, M | 1 |
2 other study(ies) available for dimyristoylphosphatidylcholine and Colorectal Neoplasms
| Article | Year |
|---|---|
Nanotherapy with hybrid liposomes for colorectal cancer along with apoptosis in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dimyristoylphosphatidylcholine; Disease Models, Animal; Female; Humans; Liposomes; Liver Neoplasms; Mice; Nanomedicine; Polyethylene Glycols; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Intravenous injection of hybrid liposomes suppresses the liver metastases in xenograft mouse models of colorectal cancer in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Colorectal Neoplasms; Dimyristoylphosphatidylcholine; Female; Fluorescent Dyes; Humans; In Situ Nick-End Labeling; Injections, Intravenous; Liposomes; Liver Neoplasms; Mice; Mice, SCID; Organ Size; Polyethylene Glycols; Survival Rate; Xenograft Model Antitumor Assays | 2012 |